Provided by Tiger Trade Technology Pte. Ltd.

Defiance Daily Target 2X Long LLY ETF

25.08
+0.12500.50%
Volume:222.10K
Turnover:5.50M
Market Cap:45.26M
PE:- -
High:25.59
Open:24.26
Low:23.82
Close:24.95
52wk High:31.19
52wk Low:12.18
Shares:1.80M
Float Shares:1.80M
Volume Ratio:2.26
T/O Rate:12.30%
Dividend:0.70
Dividend Rate:2.81%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Sector Update: Healthcare

MT Newswires Live
·
Aug 25

Eli Lilly’s New Obesity Drug LY3549492 Moves Forward With Completed Phase 1 Trial

TIPRANKS
·
Aug 25

Eli Lilly (LLY) On Foundayo Launch And Higher Outlook Faces A Rich Valuation

Simply Wall St.
·
Aug 24

Roche, Eli Lilly's Alzheimer's Blood Test Gets FDA Clearance

Reuters
·
Aug 24

Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
Aug 24

Eli Lilly: Working with Nice on Assessment of Foundayo for Potential Use on Nhs in England

THOMSON REUTERS
·
Aug 24

Eli Lilly Launches Oral Weight-Loss Pill Foundayo in UK

Reuters
·
Aug 24

Eli Lilly: Foundayo NOW Available in UK to be Prescribed for Eligible Adults Via Private Prescription

THOMSON REUTERS
·
Aug 24

Eli Lilly: in UK, Foundayo is Priced Lower than Mounjaro; Likely to be in Order of £100 to £120

THOMSON REUTERS
·
Aug 24

Eli Lilly Targets Ramadan Diabetes Market With New Orforglipron Trial

TIPRANKS
·
Aug 22

Eli Lilly’s Dulaglutide Study Sheds Light on Fasting Risks and Diabetes Care

TIPRANKS
·
Aug 22

Pharma Stocks Have Rallied. 2 Stocks to Avoid-and 2 to Buy.

Dow Jones
·
Aug 21

Eli Lilly Advances Early-Stage Eloralintide Trial: What Investors Should Watch

TIPRANKS
·
Aug 21

Eli Lilly’s Lebrikizumab Trial Completion Signals New Growth Path in Atopic Dermatitis

TIPRANKS
·
Aug 21

Eli Lilly Revenue Jumps 48% as Mounjaro and Zepbound Sales Reach $14.9B

TradingKey
·
Aug 20

Pharma Sector Doubles Down on AI Amid Hopes of Slashing Costs, Timelines

Reuters
·
Aug 20

7 Growth Stocks Holding up in a Tough Market

Dow Jones
·
Aug 20

Will Foundayo’s UK GLP‑1 Approval and New R&D Deals Change Eli Lilly's (LLY) Narrative?

Simply Wall St.
·
Aug 20

Amplitude Therapeutics: Lilly to GET Exclusive, Target-Specific Rights to Develop ,Commercialize Licensed Products Directed to Collaboration Targets

THOMSON REUTERS
·
Aug 20

Amplitude Therapeutics and Lilly Enter Strategic Collaboration to Develop Trans-Amplifying Rna Vaccines for Infectious Diseases

THOMSON REUTERS
·
Aug 20